Evogene Ltd. (NASDAQ:EVGN – Get Free Report) was the recipient of a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 180,400 shares, a decrease of 28.8% from the October 15th total of 253,400 shares. Based on an average trading volume of 143,000 shares, the short-interest ratio is presently 1.3 days.
Evogene Stock Up 2.3 %
Shares of Evogene stock opened at $0.57 on Monday. The firm has a market cap of $23.30 million, a PE ratio of -1.03 and a beta of 1.38. Evogene has a 12-month low of $0.45 and a 12-month high of $1.44. The company’s fifty day simple moving average is $0.59 and its two-hundred day simple moving average is $0.75.
Evogene (NASDAQ:EVGN – Get Free Report) last announced its earnings results on Thursday, August 17th. The biotechnology company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.02. The firm had revenue of $0.65 million for the quarter, compared to analyst estimates of $0.77 million. Evogene had a negative net margin of 943.25% and a negative return on equity of 68.84%. During the same quarter in the previous year, the firm posted ($0.21) EPS. As a group, sell-side analysts expect that Evogene will post -0.5 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Evogene
Analyst Upgrades and Downgrades
Several research firms recently commented on EVGN. Lake Street Capital raised their price objective on shares of Evogene from $2.00 to $3.00 and gave the stock a “buy” rating in a report on Friday, August 18th. StockNews.com raised shares of Evogene to a “sell” rating in a report on Thursday, October 26th. Roth Mkm raised their price objective on shares of Evogene from $1.00 to $6.00 and gave the stock a “buy” rating in a report on Friday, July 21st. Finally, Alliance Global Partners started coverage on shares of Evogene in a report on Monday, October 2nd. They issued a “buy” rating and a $1.85 price objective for the company.
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
- Five stocks we like better than Evogene
- Why Invest in High-Yield Dividend Stocks?
- MarketBeat Week in Review – 11/6 – 11/10
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Data giants MongoDB and Snowflake just got upgraded
- Why is the Ex-Dividend Date Significant to Investors?
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.